Model data suggest anthracycline-based chemotherapy may cost breast cancer survivors a median of 9.4 life-years through biological age acceleration.
|Articles|October 15, 2009
Oncology NEWS International
- Oncology NEWS International Vol 18 No 10
- Volume 18
- Issue 10
Bayer Taps New CEO
Bayer has announced that Marijn Dekkers, PhD, will succeed Werner Wenning as CEO starting October 1, 2010.
Advertisement
Bayer has announced that Marijn Dekkers, PhD, will succeed Werner Wenning as CEO starting October 1, 2010. Dr. Dekkers will join the company's board at the start of 2010 and will also serve as CEO of Bayer's healthcare division. He is currently president and CEO of Thermo Fisher Scientific.
Articles in this issue
about 17 years ago
Cancer, not HPV vaccination, hastened death of UK girlabout 17 years ago
Obesity hinders treatment in pediatric leukemiaabout 17 years ago
Posaconazole reduces infection in AML patientsabout 17 years ago
Global report warns of escalating cancer rateabout 17 years ago
New class of alpha emitters takes aim at bone metastasesabout 17 years ago
Who's Newsabout 17 years ago
Stop and smell the volatile organic compounds in lung caabout 17 years ago
Proton therapy report advises cautionAdvertisement
Related to this article
Daniel Y.C. Heng, MD, MPH, FRCPC, discussed final LITESPARK-011 data, toxicity management, and treatment sequencing in advanced renal cell carcinoma.
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
NCCN guidelines now list the ArteraAI Prostate Test for risk stratification in patients with biochemical recurrence after radical prostatectomy.
In 60 patients undergoing gastrectomy, pre-consultation video aids shortened in-person consent visits and no patient had high decisional conflict.
The robotic endoscopy system obtained detrusor muscle in 94% of resected bladder lesions among the first 20 patients treated in the VIABLE study.
Neil Mehta, MD, and Laura Kulik, MD, discussed which patients with HCC awaiting liver transplant may benefit from bridging immunotherapy.
Pembrolizumab plus SBRT produced more toxicity vs SBRT alone among patients with early-stage non–small cell lung cancer in the phase 3 KEYNOTE-867 trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
ArteraAI Prostate Test Added to NCCN Guidelines for BCR After Prostatectomy
2
Real-World Teclistamab Shows Deep Responses in R/R Multiple Myeloma Cohort
3
Adding Pembrolizumab to SBRT Does Not Improve EFS in Early-Stage NSCLC
4
Virtuoso Robotic System Earns FDA De Novo Nod for En Bloc Bladder Resection
5